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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a β-coronavirus responsible for coronavirus disease-19 (COVID-19). Spike (S) is the virally encoded surface glyco-
protein facilitating angiotensin-converting enzyme-2 (ACE-2) 
receptor binding on target cells through its receptor-binding domain 
(RBD). In a rapidly evolving field, researchers have already shown 
that, in most cases, individuals with a confirmed PCR diagnosis of 
SARS-CoV-2 infection develop IgM, IgA and IgG against the virally 
encoded surface S glycoprotein and nucleoprotein (N) within 
1–2 weeks post onset of symptoms (POS) and remain elevated after 
initial viral clearance1–7. S glycoprotein is the target for neutraliz-
ing antibodies, and a number of highly potent monoclonal anti-
bodies have been isolated that predominantly target the RBD8–11. 
A wide range of SARS-CoV-2-neutralizing antibody titres has been 
reported after infection and these vary depending on the length 
of time from infection and the severity of disease3–5,12,13. Further 
knowledge on the magnitude, timing and longevity of neutralizing 
antibody responses after SARS-CoV-2 infection is vital for under-
standing the role neutralizing antibodies might play in disease clear-
ance and protection from reinfection and/or disease. Furthermore, 
as huge emphasis has been placed on antibody reactivity assays 
to determine seroprevalence against SARS-CoV-2 in the commu-
nity and estimating infection rates, it is important to understand 
immune responses after infection to define parameters in which 
antibody tests can provide meaningful data in the absence of PCR 
testing in population studies.
Antibody responses to other human coronaviruses have been 
reported to wane over time14–17. In particular, antibody responses 
targeting endemic human α- and β-coronaviruses can last for as 
little as 12 weeks18, whereas antibodies to SARS-CoV and MERS can 
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Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms. 
However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will 
be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d 
post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show 
seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 
8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining 
neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease sever-
ity. Although some individuals with high peak infective dose (ID50 > 10,000) maintained neutralizing antibody titres >1,000 
at >60 d POS, some with lower peak ID50 had neutralizing antibody titres approaching baseline within the follow-up period. 
A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present 
study has important implications when considering widespread serological testing and antibody protection against reinfection 
with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.
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be detected in some individuals 12–34 months after infection15,19. 
Cross-sectional studies in SARS-CoV-2-infected individuals have 
so far reported lower mean neutralizing antibody titres for serum 
samples collected at later timepoints POS (23–52 d)4,7,20. However, 
there is currently a paucity of information on the kinetics and lon-
gevity of the neutralizing antibody response using multiple sequen-
tial samples from individuals in the convalescent phase beyond 
30–40 d POS3,5,21. The present study uses sequential samples from 
65 individuals with PCR-confirmed SARS-CoV-2 infection and 31 
seropositive healthcare workers (HCWs) up to 94 d POS to under-
stand the kinetics of neutralizing antibody development, and the 
magnitude and durability of the neutralizing antibody response.
We demonstrate that the magnitude of the neutralizing antibody 
response is dependent on disease severity. In some individuals who 
develop modest neutralizing antibody titres after infection (ID50 
(serum dilution that inhibits 50% infection) in the 100–300 range), 
titres become undetectable (ID50 < 50) or are approaching baseline 
after ~50 d, highlighting the transient nature of the neutralizing 
antibody response towards SARS-CoV-2 in some individuals. In 
contrast, individuals with high peak ID50 for neutralization main-
tain neutralizing antibody titres in the 1,000–3,500 range >60 d 
POS. The present study has important implications when consider-
ing protection against reinfection with SARS-CoV-2 and the dura-
bility of vaccine protection.
Results
Cohort description. The antibody response in 65 real-time quan-
titative (rtq)PCR-confirmed, SARS-CoV-2-infected individuals was 
studied over sequential timepoints. The cohort consisted of 59 indi-
viduals admitted to, and 6 HCWs at, Guy’s and St Thomas’ NHS 
Foundation Trust (GSTFT). The cohort were 78.5% male with an 
average age of 55.2 years (range 23–95 years) (Table 1). Information 
about ethnicity was not collected. A severity score was assigned to 
patients based on the maximal level of respiratory support required 
during their period of hospitalization. This cohort included the full 
breadth of COVID-19 severity, from asymptomatic infection to 
those requiring extracorporeal membrane oxygenation (ECMO) for 
severe respiratory failure. Comorbidities included diabetes mellitus, 
hypertension and obesity, with a full summary in Supplementary 
Table 1. Sequential samples were collected at timepoints between 1 
and 94 d POS and were based on the availability of discarded serum 
taken as part of routine clinical care, or as part of a HCW study.
Antibody-binding responses to SARS-CoV-2. The IgG, IgM and 
IgA response against S glycoprotein, RBD and N protein were 
measured by enzyme-linked immunosorbent assay (ELISA) over 
multiple timepoints (Fig. 1 and Extended Data Fig. 1)6. Initially, 
the optical density (OD) at 1:50 serum dilution was measured for 
302 samples from the 65 individuals (Fig. 1 and Extended Data 
Fig. 1). Only 2/65 individuals (3.1%) did not generate detectable 
antibody responses against these antigens in the follow-up period 
(Supplementary Table 2). However, sera were available only up until 
2 and 8 d POS for these two individuals and, as the mean time to 
seroconversion against at least one antigen was 12.6 d POS, it is 
likely that these individuals may have seroconverted after they had 
been discharged from hospital. IgG responses against S, RBD and N 
antigens were observed in 92.3%, 89.2% and 93.8% of individuals, 
respectively (Supplementary Table 2). The frequency of individu-
als generating an IgM response was similar to that with IgG, with 
92.3%, 92.3% and 95.4% seropositive against S glycoprotein, RBD 
and N protein, respectively. The frequency of individuals with an 
IgA response to RBD and N protein was lower, with only 72.3% and 
84.6% seropositive, respectively (Supplementary Table 2), whereas 
the IgA to S glycoprotein frequency was similar to that of the IgM 
and IgG.
A cumulative frequency analysis of positive IgG, IgA and IgM 
responses against S glycoprotein, RBD and N protein across the 
cohort did not indicate a more rapid elicitation of IgM and IgA 
responses against a particular antigen (Fig. 1a and Extended Data 
Fig. 2a) and may reflect the sporadic nature in which serum sam-
ples were collected. Therefore, a subset of donors from whom sera 
were collected over sequential timepoints early in infection (<14 d 
POS) were analysed further and different patterns of seroconver-
sion were observed (Extended Data Fig. 2b). Of these individuals, 
51.6% (16/31) showed synchronous seroconversion to IgG, IgM and 
IgA, whereas some individuals showed singular seroconversion to 
IgG (9.7%), IgM (9.7%) and IgA (9.7%). Of the individuals 58.1% 
(18/31) showed synchronous seroconversion to S glycoprotein, 
RBD and N protein, whereas singular seroconversion to N protein 
or S glycoprotein was seen in 16.1% of individuals for each.
Longitudinal analysis across sequential samples highlighted 
the rapid decline in the IgM and IgA response to all three anti-
gens after the peak OD between 20 and 30 d POS for IgM and 
IgA, respectively (Fig. 1b and Extended Data Fig. 1a), as might be 
expected after an acute viral infection14,22–24. For some individuals 
sampled at timepoints >60 d POS, the IgM and IgA responses were 
approaching baseline (Fig. 2b and Extended Data Fig. 1a). In con-
trast, the IgG OD (as measured at 1:50 dilution) remained high in 
most individuals, even up to 94 d POS (Fig. 1b and Extended Data 
Fig. 1a). However, differences were apparent when patients were 
stratified by disease severity (Fig. 2b) and when half-maximal bind-
ing (EC50) was measured (see Neutralizing antibody responses to 
SARS-CoV-2; Fig. 4b–d).
Neutralizing antibody responses to SARS-CoV-2. We next mea-
sured SARS-CoV-2 neutralization potency using a surrogate viral 
inhibition assay that uses human immunodeficiency virus type 1 
(HIV-1)-based virus particles, pseudotyped with the S glycoprotein 
of SARS-CoV-2 (refs. 25,26) and a HeLa cell-line stably expressing 
the ACE-2 receptor. Increased neutralization potency was observed 
with increasing days POS (Fig. 2a), with each individual reaching a 
peak neutralization titre (range 98–32,000) on average 23.1 d POS 
(range 1–66 d) (Extended Data Fig. 1b). Two individuals (3.1%) did 
not develop a neutralizing antibody response (ID50 < 50) consis-
tent with their lack of binding antibodies at the timepoints tested 
(<8 d POS). At peak neutralization, 7.7% had low (50–200), 10.8% 
Table 1 | Cohort description: gender, severity, age and outcome
Gender
Male, no. (%) 51 (78.5)
Female, no. (%) 14 (21.5)
Age












Still in hospital 5
Transferred to local hospital 3
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medium (201–500), 18.5% high (501–2,000) and 60.0% potent 
(2,001+) neutralizing titres. For serum samples collected after 65 d 
POS, the percentage of donors with potent neutralizing antibodies 
(ID50 2,001+) had reduced to 16.7% (Supplementary Table 3). ID50 
values correlated well with IgG-, IgM- and IgA-binding OD values 
to all three antigens, S glycoprotein, RBD and N protein (Extended 
Data Fig. 3a), and the best fit (r2) was observed between ID50 and 
the OD for S glycoprotein IgA and S glycoprotein IgM. The average 
time to detectable neutralization was 14.3 d POS (range 3–59 d). At 
earlier timepoints, some individuals displayed neutralizing activity 
before an IgG response to S glycoprotein and RBD was detectable 
by ELISA (Extended Data Fig. 2c). This highlights the capacity of 
S glycoprotein- and RBD-specific IgM and IgA to facilitate neutral-
ization in acute infection in the absence of measurable IgG27.
To determine how disease severity impacts neutralizing anti-
body titres, we compared the peak ID50 values between individuals 
with 0–3 and 4/5 disease severity (Fig. 3). Although the magnitude 
of the neutralizing antibody response at peak neutralization was 
significantly higher in the severity 4/5 group (Fig. 3a), the mean 
time taken to measure detectable neutralizing antibody titres 
(Fig. 3c) and the mean time to reach peak neutralization (Fig. 3b) 
did not differ between the two groups, suggesting that disease sever-
ity enhances the magnitude of the neutralizing antibody response 
but does not alter the kinetics. Comparison of the IgG, IgM and 
IgA OD values against S glycoprotein at peak neutralization showed 
significantly higher IgA and IgM ODs in the severity 4/5 group, 
but no significant difference was observed for IgG to S glycopro-
tein (Fig. 3d–f). This observation further highlights a potential role 
for IgA and IgM in neutralization27. Within the severity 4/5 group, 
a proportion of the patients was treated with immunomodulation 
for a persistent hyperinflammatory state characterized by fevers, 
markedly elevated C-reactive protein and ferritin, and multiorgan 
dysfunction. Despite an initial working hypothesis that antibody 
responses may differ as either a cause or a consequence of this phe-
notype, no difference in ID50 was observed between these individu-
als and the remainder of the severity 4/5 cases (Fig. 3g).
Longevity of the neutralizing antibody response. After the peak 
in neutralization, a waning in ID50 was detected in individuals 
sampled at >40 d POS. Comparison of the ID50 at peak neutral-
ization and at the final timepoint collected showed a decrease in 
almost all cases (Fig. 4a). For some individuals with severity score 
0, where peak neutralization was in the ID50 range 100–300, neu-
tralization titres became undetectable (ID50 < 50) in the pseudotype 
neutralization assay at subsequent timepoints (Figs. 4a and 2b). 
For example, donors 52 and 54 both generated a low neutralizing 
antibody response (peak ID50 of 174 and 434, respectively) but no 
neutralization could be detected (at 1:50 dilution) against the pseu-
dotyped virus 39 and 34 d after the peak ID50, respectively (Fig. 2b). 
To determine whether similar neutralization trends were observed 
with infectious wild-type virus, we selected a subset of individu-
als, representative of the range of neutralizing antibody responses 
observed using the pseudotyped virus, for further comparison. As 
shown by others, neutralization titres against authentic virus corre-
lated very well (r2 = 0.9612, P < 0.0001) with those measured using 
the SARS-CoV-2 pseudovirus8,28,29 (Extended Data Fig. 3b) and 
the same trends in neutralization decline were observed for these 
selected donors (Figs. 2b and 4f). Neutralization of wild-type virus 
could also not be detected at 1:20 dilution in donors 52 and 54 at the 
final timepoints (Fig. 2b).












































































































































































































































Fig. 1 | Kinetics of antibody development against SARS-CoV-2 antigens over time. a, A cumulative frequency analysis describing the point of  
seroconversion for each individual in the cohort. Graph shows the percentage of individuals in the cohort who become IgM, IgA or IgG positive to  
S glycoprotein, RBD and N protein each day POS. A serum sample is considered positive when the OD is fourfold above background. b, OD values  
at 1:50 serum dilution for IgM, IgA and IgG against S glycoprotein, RBD and N protein over time. Each line represents one individual (n = 65). Severities 0–3 
are shown in black and severities 4/5 in red. More than 300 pre-COVID-19 healthy control samples and >100 sera from PCR-confirmed  
SARS-CoV-2-infected individuals were previously used to develop and validate the ELISA setup6. The ELISAs were conducted once.
NATuRE MICROBIOLOGy | www.nature.com/naturemicrobiology
Articles Nature Microbiology
To gain a more quantitative assessment of the longevity of the 
IgG-binding titres specific for S glycoprotein, RBD and N protein, 
EC50 values were measured by ELISA at peak neutralization and 
compared with the EC50 at the final timepoint collected. A stronger 
correlation was observed between ID50 and EC50 compared with the 
OD values (Fig. 4e and Extended Data Fig. 3). Similar to neutraliza-
tion potency, a decrease in EC50 was observed within the follow-up 
period for S glycoprotein, RBD and N protein (Fig. 4b–d). For those 
whose neutralizing antibody titre decreased towards baseline, the 
EC50 for IgG to S glycoprotein and RBD also decreased in a similar 
manner. Finally, to determine whether the reduction in IgG titres 
might plateau, EC50 values were measured for all timepoints for four 
representative individuals, who had multiple samples collected in 
the convalescent phase (Fig. 4f). A steady decline in neutralization 
was accompanied by a decline in IgG EC50 to all antigens within the 
time window studied. Further assessment of antibody binding and 
neutralizing titres in samples collected >94 d POS will be essential to 
fully determine the longevity of the neutralizing antibody response.
Antibody responses in a HCW cohort. To gain further understand-
ing of antibody responses in SARS-CoV-2 infection, we next anal-
ysed sequential serum samples from 31 seropositive (as determined 
by an IgG response to both N protein and S glycoprotein)6 HCWs 
from GSTFT. Antibody responses in these individuals are probably 
more akin to those from individuals who were never hospitalized. 
Sera were collected every 1–2 weeks from March 2020 to June 2020. 
Acute infection, as determined by rtqPCR, was not measured rou-
tinely, but symptoms relating to COVID-19 were recorded.
IgG and IgM binding to S glycoprotein, RBD and N protein by 
ELISA and pseudovirus neutralization titres were measured over 
time (Fig. 5a and Extended Data Fig. 4a). Similar to the patient 
cohort, ID50 values correlated with the OD values for IgG and IgM 
against S glycoprotein and RBD (Extended Data Fig. 4b). However, 
in contrast, the IgM and IgG responses to N protein in HCWs cor-
related poorly (r2 = 0.030 and 0.381, respectively) (Extended Data 
Fig. 4b). Comparison of the peak ID50 between asymptomatic 
individuals (6/31) and symptomatic HCWs (25/31) showed a very 
















































































































Fig. 2 | Kinetics of neutralizing antibody responses in SARS-CoV-2 infection. a, Neutralizing antibody ID50 changes related to days POS. ID50 was 
measured using HIV-1-based virus particles (PVs), pseudotyped with the S glycoprotein of SARS-CoV-2. Each line represents one individual (n = 65). 
Severities 0–3 are shown in black and severities 4/5 in red. Pre-COVID-19 healthy control samples did not show any neutralization at a 1:20 serum dilution 
(Supplementary Table 3). A subset of neutralization experiments (n = 25) was conducted twice, yielding similar results. ID50 values for the remaining 
samples were measured once. b, Example kinetics of antibody responses (IgM, IgA, IgG binding to S glycoprotein, RBD and N protein, and ID50 against PVs 
and wild-type virus) for four individuals during acute infection and the convalescent phase. Graphs show comparison between disease-rated severity 0 
(left) and disease-rated severity 4 (right). The cut-off for the pseudovirus and wild-type virus neutralization assays are 1:50 and 1:20, respectively.
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similar mean peak ID50. In contrast, both groups had lower mean 
peak ID50 values compared with hospitalized individuals in the 0–3 
and 4/5 severity groups (Fig. 5b). Importantly, some asymptomatic 
individuals generated neutralization titres >1,000. Similar to the 
cohort with confirmed SARS-CoV-2 infection, a decline in ID50 was 
observed after peak neutralization. For many individuals with peak 
ID50 in the 100–500 range, neutralization was approaching baseline 
after 50 d POS (Fig. 5c). As the mean peak ID50 was lower in the 
HCW cohort, the decline in neutralizing antibody titres towards 
baseline was more frequent compared with the patient cohort.
Discussion
The sequential serum samples collected up to 94 d POS allowed 
evaluation of the kinetics and longevity of the neutralizing antibody 
response in much greater detail than has hitherto been possible. As 
exemplified by Figs. 2b and 4f, the kinetics of the antibody response 
in SARS-CoV-2 infection is typical of an acute viral infection14,22–24. 
The peak in neutralizing antibodies arises due to a rapid production 
of short-lived plasmablasts30 that secrete high titres of antibodies; 
this is subsequently followed by a decline in virus-specific antibod-
ies as these cells die. We observed a wide range of peak neutral-
izing antibody titres (98–32,000), similar to other cross-sectional 
cohorts21,4,31, and disease severity was associated with higher neu-
tralizing antibody titres. It is not clear yet why neutralizing anti-
body responses correlate with disease severity32. A higher viral load 
may lead to more severe disease and generate a stronger antibody 
response through increased levels of viral antigen. Alternatively, 
antibodies could have a causative role in disease severity, although 
there is currently no evidence for antibody-dependent enhance-
ment in COVID-1933.
Comparison of the peak ID50 for each individual, and ID50 at the 
final timepoint collected, showed a decline in neutralizing titres 
regardless of disease severity. The decline in neutralizing antibodies 
was mirrored in the reduction in IgG-binding titres (EC50) to S gly-
coprotein and RBD and also IgM and IgA binding to S glycoprotein 
and RBD (OD values) for the PCR+ cohort (Fig. 4b). For some indi-
viduals with peak ID50 in the 100–300 range, neutralizing titres were 
at, or below, the level of detection (ID50 < 50) after only ~50 d from 
the measured peak of neutralization (although IgG binding to N 
protein, S glycoprotein and RBD was still detected). This trend was 
also seen in the HCW cohort, and reveals that, in some individuals, 
SARS-CoV-2 infection generates only a transient neutralizing anti-
body response that rapidly wanes. For most individuals with peak 
ID50 titres >4,000, despite a decline in neutralizing antibody titres 
ranging from 2-fold to 23-fold over an 18- to 65-d period, neutral-
izing antibody titres remain in the 1,000–3,500 range at the final 
timepoint. Although the lowest serum dilution used in the pseu-
dovirus neutralization assay is relatively high (1:50), donors who 
lacked detectable neutralization also showed no neutralizing activ-
ity against wild-type virus at 1:20.
The magnitude of the following decline in neutralizing anti-
body titres reported here is similar to that observed in several 
newly reported pre-prints12,13,20,31,34–39. In these studies, similar to 
our observations, those who generated a high neutralizing anti-
body titre still had high neutralizing antibody titres regardless of 
the initial decline12,13,31,35,39 and, for those with lower disease sever-
ity, two studies reported 7/34 (ref. 12) and 5/80 (ref. 31) individuals 
with a decline to undetectable neutralizing antibodies (ID50 < 20 or 
ID50 < 50, respectively) at the last timepoint studied. In contrast, 
several studies report a sustained antibody response in the first 
3 months after SARS-CoV-2 infection, but these studies report 
changes in binding antibodies only34,37,38. Although binding titres to 
S glycoprotein and RBD correlate with neutralizing antibody titres, 
this difference in antibody measurement may account for the differ-
ences in kinetics described. Further follow-up in these longitudinal 
cohorts is required to determine whether the neutralizing antibody 
decline will continue on a downward trajectory or whether the 
neutralizing antibody titres will plateau to a steady state, facilitated 
through their production by long-lived plasma cells. Importantly, 
class-switched IgG memory B cells against S glycoprotein and RBD 
have been detected in blood of COVID-19 patients, showing that 
memory responses are generated during infection that have the 
potential to be activated to rapidly produce neutralizing antibodies 
on re-exposure to SARS-CoV-2 and prevent infection and/or dis-
ease8,29,40,41. Indeed, highly potent neutralizing monoclonal antibod-
ies with protective capacity have been isolated from memory B cells 
of both symptomatic and asymptomatic individuals8,10,42.
The longevity of neutralizing antibody responses to other 
human coronaviruses has been previously studied14–17. In contrast 
to SARS-CoV-2 infection, SARS-CoV infection typically caused 
more severe disease and asymptomatic, low-severity cases were less 
common43. The neutralizing antibody response after SARS-CoV 
infection in a cohort of hospitalized patients peaked around day 30 
(average titre 1:590)16 and a general waning of the binding IgG and 























































































































































Fig. 3 | Impact of disease severity on antibody responses in SARS-CoV-2 
infection. a–c, Comparison for individuals with disease severity 0–3 (n = 33 
individuals) or 4/5 (n = 32 individuals) for peak ID50 of neutralization (a; 
P < 0.0001), the time POS to reach peak ID50 (b; P = 0.674) and the time POS 
to detect neutralizing activity (c; P = 0.9156). ID50 measured using  
HIV-1-based virus particles, pseudotyped with S glycoprotein of SARS-CoV-2. 
d–f, Comparison of OD values for individuals with 0–3 or 4/5 disease severity 
for IgG (d; P = 0.0635), IgM (e; P = 0.0003) and IgA (f; P = 0.0018) against S 
glycoprotein measured at peak ID50. g, Comparison of the peak ID50 value for 
individuals who were treated for hyperinflammation (HI; n = 14 individuals) 
or not treated (n = 18 individuals), and had 4/5 disease severity (P > 0.999). 
Statistical significance was measured using a Mann–Whitney two-sided test 
U-test. **P < 0.002, ***P < 0.0002, ****P < 0.0001. NS, not significant. The 
line represents the mean ID50 for each group.
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neutralizing antibody titres of 1:10 were detected in 17/18 individu-
als after 540 d16. In a second study, low neutralizing antibody titres 
(mean 1:28) were still detected up to 36 months post-infection in 
89% of individuals19. The lower neutralizing antibody responses in 
the 0–3 disease severity cases in our two cohorts may reflect more 
the immune response to endemic seasonal coronaviruses (that 
is, those associated with the common cold), which has also been 
reported to be more transient and where reinfections do occur2,18. 
For example, individuals experimentally infected with endemic 
α-coronavirus 229E, generated high antibody titres after 2 weeks, 
which rapidly declined in the following 11 weeks and, by 1 year, the 
mean antibody titres had reduced further14. Subsequent virus chal-
lenge led to reinfection (as determined by virus shedding), yet indi-
viduals showed no cold symptoms14.
The neutralizing antibody titre required for protection from rein-
fection and/or disease in humans is not yet understood. Neutralizing 
monoclonal antibodies isolated from SARS-CoV-2-infected indi-
viduals can protect from disease in animal challenge models in a 
dose-dependent manner, highlighting neutralizing antibodies as a 
correlate of protection9–11. SARS-CoV-2-infected rhesus macaques, 
which developed neutralizing antibody titres of ~100 (range 
83–197), showed no clinical signs of illness when challenged 35 d 
after primary infection44. However, virus was still detected in nasal 
swabs, albeit 5 log lower than in primary infection, suggesting 
immunological control rather than sterilizing immunity. In con-
trast, a second study showed no detectable virus after re-challenge 
with neutralizing antibody titres in the 8–20 range45. Many cur-
rent COVID-19 vaccine efforts focus on eliciting a robust neutral-
izing antibody response to provide protection from infection. Our 
observation that neutralizing antibody titres decline to low levels 
after low-severity disease suggests that vaccines should aim to elicit 
titres similar to those generated by severe disease and boosting 
may be required to maintain neutralizing antibody titres. The first 
results from phase I clinical trials showed peak median neutralizing 
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ID50 (PV) ID50 (live virus)
Fig. 4 | Longevity of the neutralizing antibody response. a, ID50 at peak neutralization (measured using HIV-1-based viral particles, pseudotyped with the 
S glycoprotein of SARS-CoV-2) is plotted with the donor-matched ID50 at the last timepoint from which serum was collected. Only individuals in whom the 
peak ID50 occurs before the last timepoint and the last timepoint is >30 d POS are included in this analysis (n = 35). The dotted line represents the cut-off 
for the pseudovirus neutralization assay. b–d, EC50 values for IgG binding to S glycoprotein (b), RBD (c) and N protein (d) were calculated at timepoints 
with peak ID50 and the final timepoint sera were collected. EC50 at peak neutralization is plotted with the donor-matched EC50 at the last timepoint sera were 
collected. Individuals with a disease severity 0–3 are shown in black and those with 4/5 in red. The dotted line represents the cut-off for EC50 measurement. 
The ELISAs to determine EC50 values were conducted once. e, Correlation of ID50 with IgG EC50 against S glycoprotein (r2 = 0.7924), RBD (r2 = 0.6781) and 
N protein (r2 = 0.4533) (Spearman’s correlation, r; a linear regression was used to calculate the goodness of fit, r2). f, Change in IgG EC50 measured against 
S glycoprotein, RBD and N protein, and ID50 using pseudovirus and wild-type virus over time for four example patients (all disease severity 4). The lowest 
dilution used for the pseudovirus and wild-type virus neutralization assays are 1:50 and 1:20, respectively.
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antibody titres of 654 and 3,906 after two doses of a messenger RNA 
vaccine encoding S glycoprotein of SARS-CoV-2 (mRNA-1273) by 
Moderna46 and two doses of a recombinant nanoparticle S glycopro-
tein vaccine by Novavax47, respectively. Vaccine challenge studies in 
macaques can give some limited insights into neutralizing antibody 
titres required for protection from reinfection48–51. A DNA vaccine 
encoding S protein of SARS-CoV-2 generated neutralizing antibody 
titres between 100 and 200, which strongly correlated with a lower-
ing of the viral load (up to 3 log)51. Further, vaccine mRNA-1273 
generated geometric mean titres of 3,481 in macaques, which were 
shown to prevent viral replication in the upper and lower respira-
tory tracts52. The role that T cell responses generated through either 
infection53 or vaccination play in controlling disease cannot be dis-
counted in these studies, and further definition of the correlates and 
longevity of vaccine-induced protection is needed. Taken together, 
despite the lower neutralizing antibody titres measured at the lat-
est timepoints in some individuals, neutralizing antibody titres may 
still be sufficient to provide protection from COVID-19 for a period 
of time. However, follow-up studies involving sequential PCR test-
ing and serological analysis in these individuals will be critical for 
understanding the ability of neutralizing antibodies to protect from 
reinfection in humans.
In summary, using sequential samples from SARS-CoV-
2-infected individuals collected up to 94 d POS, we demonstrate a 
typical antibody response after an acute viral infection where a peak 
response was detected 3–4 weeks post-infection, which then wanes. 
For those who develop a low neutralizing antibody response (ID50 
100–300), titres can return to baseline over a relatively short period, 
whereas those who develop a robust neutralizing antibody response 
maintain titres >1,000 despite the initial decline. Further studies 
using samples collected from these individuals at extended time-
points are required to determine the longevity of the neutralizing 
antibody response as well as the neutralizing antibody threshold for 
protection from reinfection and/or disease.
Methods
Ethics. Surplus serum from patient biochemistry samples taken as part of routine 
care was retrieved at the point of being discarded, aliquoted, stored and linked to 
a limited clinical dataset by the direct care team, before anonymization. Work was 
undertaken in accordance with the UK Policy Framework for Health and Social 
Care Research and approved by the Risk and Assurance Committee at GSTFT. 
Serum was collected from consenting HCWs with expedited approval from the 
GSTFT R&D office, occupational health department and medical director.
Patient and sample origin. Some 269 individual venous serum samples,  
collected at St Thomas’ Hospital, London from 59 patients diagnosed as 
SARS-CoV-2 positive via RT–PCR, were obtained for serological analysis. 
Samples ranged from 1 d to 94 d after onset of self-reported symptoms or, in 
asymptomatic cases, days after a positive PCR result. Patient information is given 
in Supplementary Table 1.
HCW cohort. Sequential serum samples were collected every 1–2 weeks 
from HCWs at GSTFT between 13 March and 10 June 2020. Seropositivity to 
SARS-CoV-2 was determined using sera collected in April and early May 2020, 
using ELISA. Individuals were considered seropositive if sera (diluted 1:50) gave an 
OD for IgG against both N protein and S glycoprotein that was fourfold above the 
negative control sera6. Self-reported COVID-19-related symptoms were recorded 
by participants and days POS in seropositive individuals was determined using this 
information. For asymptomatic, seropositive individuals, days POS was defined 
from the first timepoint at which SARS-CoV-2 antibodies were detected. Six 
participants had infection confirmed by PCR and were included with the PCR+ 
hospitalized patients in the initial analysis. An additional 31 HCWs were found to 
be seropositive and formed the HCW cohort.
COVID-19 severity classification. The score, ranging from 0 to 5, was devised 
to mitigate underestimating disease severity in patients not for escalation above 
level one (ward-based) care. Patients diagnosed with COVID-19 were classified as 
follows:
(0) Asymptomatic or no requirement for supplemental oxygen;
 (1) Requirement for supplemental oxygen (fraction of inspired oxygen 
(FiO2) < 0.4) for at least 12 h;
(2) Requirement for supplemental oxygen (FiO2 ≥ 0.4) for at least 12 h;
 (3) Requirement for non-invasive ventilation/continuous positive airway 
pressure or proning or supplemental oxygen (FiO2 > 0.6) for at least 12 h, and 
not a candidate for escalation above level one (ward-based) care;
 (4) Requirement for intubation and mechanical ventilation or supplemental 
oxygen (FiO2 > 0.8) and peripheral oxygen saturations <90% (with no history of 
type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h;
(5) Requirement for ECMO.
Cell lines. HEK293 freestyle cells were obtained from Thermo Fisher Scientific 
(catalogue no. R79007). HEK293T/17 cells were obtained from the American 
Type Culture Collection (ATCC CRL-11268). HeLa cells stably expressing ACE-2 
(HeLa-ACE-2) were obtained from J. Voss (Scripps)10. Vero-E6 cells were obtained 
from W. Barclay (Imperial College London). All cell lines tested negative for 
Mycoplasma. No authentication was performed. No commonly misidentified cell 
lines were used.
Protein expression. The N protein of SARS-CoV-2 comprised residues 48–365 
with an N-terminal, uncleavable, hexahistidine tag. N protein was expressed 


















































Fig. 5 | Antibody responses in a HCW cohort. a, ID50 values plotted against the time POS at which sera were collected. Each line represents one individual 
(n = 37). ID50 was measured using HIV-1-based viral particles pseudotyped with the S glycoprotein of SARS-CoV-2. Asymptomatic individuals are shown in 
green, symptomatic individuals in black and HCWs with PCR-confirmed SARS-CoV-2 infection in red (for comparison). The vertical dotted line represents 
day 0 POS. Of seropositive individuals, 80.6% (25/31) recorded COVID-19-compatible symptoms (including fever, cough and anosmia) since 1 February 
2020, and 19.4% (6/31) reported none. A subset of neutralization experiments (n = 10) were conducted twice, yielding similar results. ID50 values for 
the remaining samples were measured once. b, Comparison of the peak ID50 between asymptomatic individuals (n = 10, includes 7 HCW and 3 hospital 
patients), HCWs (n = 24 symptomatic HCWs with no PCR test), and PCR+ individuals with severity either 0–3 (n = 28) or 4/5 (n = 32). The two PCR+ 
individuals, who were sampled at early timepoints (<8 d POS) and did not seroconvert, were not included in this analysis. c, ID50 at peak neutralization 
is plotted with the donor-matched ID50 at the last timepoint sera were collected. The dotted line represents the cut-off (1:50) for the SARS-CoV-
2-pseudovirus neutralization assay. Asymptomatic donors are shown in green and symptomatic donors in black.
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in Escherichia coli using autoinducing medium for 7 h at 37 °C, and purified 
using immobilized metal affinity chromatography, size exclusion and heparin 
chromatography. N protein was obtained from L. James and J. Luptak at  
LMB, Cambridge.
S glycoprotein consisted of the pre-fusion S ectodomain (residues 1–1138) 
with a GGGG substitution at the furin cleavage site (amino acids 682–685), 
proline substitutions at amino acid positions 986 and 987, and an N-terminal T4 
trimerization domain followed by a Strep-tag II (ref. 8). The protein was expressed 
in HEK293F cells (Invitrogen). One litre of cells (density of 1.5 × 106 cells ml−1) 
were transfected with 325 µg DNA using PEI-Max (1 mg ml−1, Polysciences) at 
a 1:3 ratio and supernatant was harvested after 7 d. The protein was purified 
using StrepTactinXT Superflow high-capacity 50% suspension according to 
the manufacturer’s protocol by gravity flow (IBA Life Sciences). The plasmid 
was obtained from P. Brouwer, M. van Gils and R. Sanders at the University of 
Amsterdam.
The RBD protein (encoded by residues 319–541) has the natural N-terminal 
signal peptide of S glycoprotein fused at the start of the RBD sequence and 
is joined to a C-terminal hexahistidine tag. RBD was expressed in HEK293F 
cells (Invitrogen). Then, 500 ml of cells (density of 1.5 × 106 cells ml−1) was 
transfected with 1,000 µg DNA using PEI-Max (1 mg ml−1, Polysciences) at a 
1:3 ratio. Supernatant was harvested after 7 d and protein purified using nickel–
nitrilotriacetic acid agarose beads. The RBD plasmid was obtained from  
F. Krammer at Mount Sinai University1.
ELISA protocol. ELISAs were carried out as previously described6,30,54. All sera/
plasma were heat inactivated at 56 °C for 30 min before use. High-binding ELISA 
plates (Corning, 3690) were coated with antigen (N protein, S glycoprotein or 
RBD) at 3 µg ml−1 (25 µl per well) in phosphate-buffered serum (PBS), either 
overnight at 4 °C or for 2 h at 37 °C. Wells were washed with PBS-T (PBS with 
0.05% Tween-20) and then blocked with 100 µl of 5% milk in PBS-T for 1 h at room 
temperature. The wells were emptied and serum diluted at 1:50 in milk was added 
and incubated for 2 h at room temperature. Control reagents included CR3009 
(2 µg ml−1), CR3022 (0.2 µg ml−1), negative control plasma (1:25 dilution), positive 
control plasma (1:50) and blank wells. Wells were washed with PBS-T. Secondary 
antibody was added and incubated for 1 h at room temperature. IgM was detected 
using goat-anti-human-IgM-HRP (horseradish peroxidase) (1:1,000) (Sigma, 
catalogue no. A6907), IgG was detected using goat-anti-human-Fc-AP (alkaline 
phosphatase) (1:1,000) (Jackson, catalogue no. 109-055-098) and IgA was detected 
goat-anti-human-IgA-HRP (1:1,000) (Sigma, catalogue no. A0295). Wells were 
washed with PBS-T and either AP substrate (Sigma) was added and read at  
405 nm (AP) or one-step 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Thermo 
Fisher Scientific) was added and quenched with 0.5 M H2S04 before reading at 
450 nm (HRP).
ELISA measurements were performed in duplicate and the mean of the two 
values was used.
EC50 values were measured using a titration of serum starting at 1:50 and 
a fivefold dilution series. EC50 values were calculated using GraphPad Prism. 
Measurements were carried out in duplicate.
SARS-CoV-2-pseudotyped virus preparation. Pseudotyped HIV virus 
incorporating the S glycoprotein of SARS-Cov-2 was produced in a 10-cm dish 
seeded the day before with 3.5 × 106 HEK293T/17 cells in 10 ml of complete 
Dulbecco’s modified Eagle’s medium (DMEM-C, 10% fetal bovine serum 
(FBS) and 1% penicillin–streptomycin) containing 10% (v:v) FBS, 100 IU ml−1 
of penicillin and 100 μg ml−1 of streptomycin. Cells were transfected using 
35 μg of PEI-Max (1 mg ml−1, Polysciences) with: 1,500 ng of HIV-luciferase 
plasmid, 1,000 ng of HIV 8.91 gag/pol plasmid and 900 ng of the SARS-CoV-2 S 
glycoprotein plasmid25,26. The medium was changed 18 h post-transfection and the 
supernatant was harvested 48 h post-transfection. Pseudotype virus was filtered 
through a 0.45-μm filter and stored at −80 °C until required.
Viral entry inhibition assay with SARS-CoV-2-pseudotyped virus. Neutralization 
assays were conducted as previously described54. Serial dilutions of serum samples 
(heat inactivated at 56 °C for 30 min) were prepared with DMEM (10% FBS  
and 1% penicillin–streptomycin) and incubated with pseudotype virus for 1 h 
at 37 °C in 96-well plates. Next, HeLa cells stably expressing the ACE-2 receptor 
(provided by J. Voss, Scripps Research) were added (12,500 cells per 50 µl per well) 
and the plates were left for 72 h. The infection level was assessed in lysed cells 
with the Bright-Glo luciferase kit (Promega), using a Victor X3 Multilabel Reader 
(Perkin Elmer). Measurements were performed in duplicate and duplicates used to 
calculate the ID50.
Virus strain and propagation. Vero-E6 (Cercopithecus aethiops-derived epithelial 
kidney cells, provided by W. Barclay, Imperial College London) cells were grown 
in DMEM (Gibco) supplemented with GlutaMAX, 10% FBS and 20 µg ml−1 of 
gentamicin, and incubated at 37 °C with 5% CO2. SARS-CoV-2 Strain England 2 
(England 02/2020/407073) was obtained from Public Health England. The virus 
was propagated by infecting 60–70% confluent Vero-E6 cells in T75 flasks, at a 
multiplicity of infection of 0.005 in 3 ml of DMEM supplemented with GlutaMAX 
and 10% FBS. Cells were incubated for 1 h at 37 °C before adding 15 ml of the same 
medium. Supernatant was harvested 72 h post-infection after visible cytopathic 
effect, and filtered through a 0.22-µm filter to eliminate debris, aliquoted and 
stored at −80 °C. The infectious virus titre was also determined by plaque assay in 
Vero-E6 cells.
Live virus neutralization assay. Vero-E6 cells were seeded at a concentration of 
20,000 cells per 100 μl per well in 96-well plates and allowed to adhere overnight. 
Serial dilutions of serum samples (heat inactivated at 56 °C for 30 min) were 
prepared with DMEM (2% FBS and 1% PBS) and incubated with authentic 
SARS-CoV-2 for 1 h at 37 °C. The medium was removed from the pre-plated 
Vero-E6 cells and the serum–virus mixtures were added to the Vero-E6 cells 
and incubated at 37 °C for 24 h. This virus/serum mixture was aspirated and 
each well was fixed with 150 µl of 4% formalin at room temperature for 30 min 
and then topped up to 300 µl using PBS. The cells were washed once with PBS 
and permeabilized with 0.1% Triton-X in PBS at room temperature for 15 min. 
The cells were washed twice with PBS and blocked using 3% milk in PBS at 
room temperature for 15 min. The blocking solution was removed and an N 
protein-specific monoclonal antibody (murinized-CR3009) was added at 2 µg ml−1 
(diluted using 1% milk in PBS) at room temperature for 45 min. The cells were 
washed twice with PBS and horse anti-mouse-IgG-conjugated to HRP was added 
(1:2,000 in 1% milk in PBS, Cell Signaling Technology, catalogue no. S7076) at 
room temperature for 45 min. The cells were washed twice with PBS, developed 
using TMB substrate for 30 min and quenched using 2M H2SO4 before reading  
at 450 nm.
Measurements were performed in duplicate and the duplicates used to  
calculate the ID50.
Statistical analysis. Analyses were performed using GraphPad Prism v.8.4.2.
Reporting summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The source data generated during the current study are available as supplementary 
information.
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Extended Data Fig. 1 | Cross-sectional SARS-CoV-2 Ab responses. a, IgM, IgA and IgG OD values against S glycoprotein, RBD and N protein are binned 
based on days post-onset of symptoms (POS) for 302 separate serum samples taken sequentially from 65 individuals. The data is grouped based on 
disease severity, 0–3 (black) and 4/5 (red). The mean OD value is shown for each time window for both the 0–3 (black line) and 4/5 (red line) severity 
groups. OD = optical density. b, ID50 measured using the SARS-CoV-2 pseudotype neutralization assay are binned based on days post-onset of symptoms 
(POS). The data is grouped based on disease severity, 0–3 (black) and 4/5 (red). The mean ID50 values are shown for each time window for both the 0–3 
(black line) and 4/5 (red line) severity groups. The ELISA assays were conducted once. A subset of neutralization experiments (n=25) were conducted 
twice yielding similar results.
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Extended Data Fig. 2 | Antibody isotype and specificity at the timepoint for which an individual became seropositive. a, A cumulative frequency analysis 
describing the seroconversion in the hospitalized cohort. Graph shows the percentage of individuals in the cohort that become IgM, IgA or IgG seropositive 
against S glycoprotein, RBD and N protein each day POS. b, Patterns of seroconversion based on antigen and antibody isotype for a subset of donors from 
whom sera was collected over sequential early time points (<14 days POS, n=31). For individuals with at least 2 sera collected <14 days POS, the first 
antigen(s) and antibody isotype(s) that gave an OD that was 4-fold above background is reported. c) Pseudovirus neutralization and ELISA binding at 
early time points POS for a subset of individuals (n=15) where there were measurable neutralization titres but IgG binding to S was low (OD <0.2) and 
IgM and/or IgA to S is higher (OD >0.4). Each bar shows data for one patient only.
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Extended Data Fig. 3 | Correlations between OD values and ID50. a, Correlation of ID50 measured against SARS-CoV-2 pseudovirus with IgG (blue), IgM 
(black), IgA (red) OD values (at 1:50) against S glycoprotein, RBD and N protein (Spearman correlation, r). b, Correlation of ID50 measured using wild-type 
virus and ID50 measured using pseudovirus neutralization assays (Spearman correlation, r). A linear regression was used to calculate the goodness 
of fit (r2). The dotted lines represent the lowest serum dilution used in each assay. The lowest dilution used for the pseudovirus and wild-type virus 
neutralization assays are 1:50 and 1:20, respectively.
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Extended Data Fig. 4 | Ab responses in a healthcare worker cohort. a, Ab responses (IgG and IgM to S glycoprotein, RBD and N protein) over time.  
Each line represents one individual. Asymptomatic individuals shown in green, symptomatic individuals shown in black and PCR+ HCW shown in red (for 
comparison). The dotted line represents day 0 POSs. b, Correlation of ID50 with IgG and IgM OD values against S glycoprotein and N protein (Spearman 
correlation, r). A linear regression was used to calculate the goodness of fit (r2). The ELISA assays were conducted once. A subset of neutralization 
experiments were conducted twice yielding similar results.
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